Market Trends– category –
-
2026 Digital Blood Sugar Meters: CGM Revolutionizes Metabolic Awareness with Real-Time Trends and Historical Data
[Unnamed Health Publication] Unknown Overview An analysis of digital blood sugar meters in 2026 highlights the distinction between traditional meters, which provide single readings, and Continuous Glucose Monitoring (CGM) devices that of... -
Abbott’s FreeStyle Libre Offers 10-Day Real-Time Glucose Monitoring for Diabetes Patients Aged 4 and Up
Health Insider Canada Overview Abbott Laboratories' FreeStyle Libre system provides continuous glucose monitoring for diabetes patients aged four and older, utilizing a small wearable sensor and a smartphone app. This system delivers rea... -
Dorsey & Whitney Trust CO LLC Sells Abbott Laboratories Shares Amidst Focus on Libre Duo CE Mark Approval
MarketBeat USA Overview Dorsey & Whitney Trust CO LLC has reduced its holdings in Abbott Laboratories shares. Despite this divestment, Abbott is gaining significant attention for its recent CE Mark approval of Libre Duo, an innovativ... -
Erste Group Bank Adjusts Abbott’s FY2027 Earnings Outlook Downward, Highlights Libre Duo CE Mark as Key Growth Driver
MarketBeat USA Overview Erste Group Bank has slightly lowered its fiscal year 2027 earnings outlook for Abbott Laboratories, yet emphasizes Abbott's recent CE Mark approval for its innovative Libre Duo dual glucose-ketone sensing technol... -
Diabetes Devices Dominate FDA MAUDE Reports 2020-2025 with Over 50% of Adverse Events, Dexcom Largest Single Reporter
Global MedTech Expert | 10× MedTech Global Access Unknown Overview An analysis of 14.4 million FDA MAUDE adverse event reports from 2020 to 2025 reveals that diabetes-related devices account for over half of all reported events. Continuo... -
Supply Chain Integrity Under Fire: Pharmsource Denies Knowledge of Stolen, Recalled Dexcom G7 Sensors
Investing.com 南アフリカ Overview Pharmaceutical wholesaler Pharmsource LLC denies knowing that Dexcom G7 continuous glucose monitoring (CGM) sensors it acquired were stolen post-disposal and resold, despite being originally slated for d... -
Goodman Advisory Group Invests $1.29 Million in DexCom Amidst Strong Q1 Performance, Revenue Soars 15% to $1.19 Billion
MarketBeat USA Overview Goodman Advisory Group has made a strategic investment of $1.29 million in DexCom, a leading continuous glucose monitoring (CGM) company, following DexCom's strong first-quarter earnings report. The company achiev... -
Zoll Corporation Receives FDA Warning Letter Over Quality Concerns Regarding AccuVent Sensor Malfunction Handling
MedTech Dive USA Overview Zoll Corporation has received a Warning Letter from the U.S. FDA regarding quality concerns, specifically citing inadequate handling of complaints related to malfunctions of its AccuVent sensors used in ventilat... -
i-SENS’s CareSens Air CGM Secures Belgian Reimbursement, Paving the Way for Expanded European Market Penetration
i-SENS (アジア経済新聞経由) South Korea, ベルギー Overview South Korean medical device firm i-SENS has achieved a critical milestone with its "CareSens Air" continuous glucose monitoring (CGM) device, securing public insurance reimbursem... -
FiberSense AG Secures CE Mark for Groundbreaking 28-Day Optical CGM System, Targeting European Market Entry
PR Newswire (The Storm Media経由) Switzerland, EU Overview Swiss medtech firm FiberSense AG has obtained CE Mark approval for its continuous glucose monitoring (CGM) system as a Class IIb medical device under EU Regulation 2017/745. This...
